Pentafecta for Radical Nephroureterectomy in Patients with High-Risk Upper Tract Urothelial Carcinoma: A Proposal for Standardization of Quality Care Metrics.

UTUC nephroureterectomy pentafecta quality upper tract urothelial carcinoma

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
31 Mar 2022
Historique:
received: 05 03 2022
revised: 21 03 2022
accepted: 22 03 2022
entrez: 12 4 2022
pubmed: 13 4 2022
medline: 13 4 2022
Statut: epublish

Résumé

Background: Measuring quality of care indicators is important for clinicians and decision making in health care to improve patient outcomes. Objective: The primary objective was to identify quality of care indicators for patients with upper tract urothelial carcinoma (UTUC) and to validate these in an international cohort treated with radical nephroureterectomy (RNU). The secondary objective was to assess the factors associated with failure to validate the pentafecta. Design: We performed a retrospective multicenter study of patients treated with RNU for EAU high-risk (HR) UTUC. Outcome measurements and statistical analysis: Five quality indicators were consensually approved, including a negative surgical margin, a complete bladder-cuff resection, the absence of hematological complications, the absence of major complications, and the absence of a 12-month postoperative recurrence. After multiple imputations and propensity-score matching, log-rank tests and a Cox regression were used to assess the survival outcomes. Logistic regression analyses assessed predictors for pentafecta failure. Results: Among the 1718 included patients, 844 (49%) achieved the pentafecta. The median follow-up was 31 months. Patients who achieved the pentafecta had superior 5-year overall- (OS) and cancer-specific survival (CSS) compared to those who did not (68.7 vs. 50.1% and 79.8 vs. 62.7%, respectively, all p < 0.001). On multivariable analyses, achieving the pentafecta was associated with improved recurrence-free survival (RFS), CSS, and OS. No preoperative clinical factors predicted a failure to validate the pentafecta. Conclusions: Establishing quality indicators for UTUC may help define prognosis and improve patient care. We propose a pentafecta quality criteria in RNU patients. Approximately half of the patients evaluated herein reached this endpoint, which in turn was independently associated with survival outcomes. Extended validation is needed.

Identifiants

pubmed: 35406553
pii: cancers14071781
doi: 10.3390/cancers14071781
pmc: PMC8997024
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

J Endourol. 2021 Mar;35(3):312-318
pubmed: 33081512
Eur Urol Focus. 2019 Mar;5(2):205-223
pubmed: 29154042
BJU Int. 2012 Jan;109(1):77-82
pubmed: 21631698
J Natl Compr Canc Netw. 2020 Mar;18(3):329-354
pubmed: 32135513
Multivariate Behav Res. 2011 May;46(3):399-424
pubmed: 21818162
Eur Urol. 2015 Jun;67(6):1122-1133
pubmed: 25488681
Cochrane Database Syst Rev. 2019 May 18;5:CD013160
pubmed: 31102534
Eur Urol. 2018 Feb;73(2):242-251
pubmed: 28342641
World J Urol. 2017 Mar;35(3):379-387
pubmed: 27604375
Urology. 2010 Jan;75(1):118-24
pubmed: 19864000
Stat Med. 2011 Feb 20;30(4):377-99
pubmed: 21225900
J Urol. 2013 Jan;189(1):36-42
pubmed: 23164381
J Clin Oncol. 2013 Apr 10;31(11):1422-7
pubmed: 23460707
J Urol. 2013 May;189(5):1662-9
pubmed: 23103802
J Urol. 2015 Dec;194(6):1567-74
pubmed: 26094807
Eur Urol. 2011 Oct;60(4):776-83
pubmed: 21798659
BJU Int. 2017 Feb;119(2):268-275
pubmed: 27322735
Eur Urol. 2012 Feb;61(2):245-53
pubmed: 21975249
J Urol. 2017 Mar;197(3 Pt 1):580-589
pubmed: 27670916
Eur Urol. 2014 Aug;66(2):181-3
pubmed: 24361259
J Urol. 2010 Aug;184(2):453-8
pubmed: 20620397
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
J Urol. 2013 Apr;189(4):1236-42
pubmed: 23079376
Int J Urol. 2010 Oct;17(10):848-54
pubmed: 20812922
Curr Opin Urol. 2021 Jul 1;31(4):291-296
pubmed: 33973537
Urol Oncol. 2019 Oct;37(10):758-764
pubmed: 31378586
Eur Urol. 2014 Jan;65(1):210-7
pubmed: 22579047
Syst Rev. 2014 Dec 23;3:150
pubmed: 25540016
BJU Int. 2020 Jan;125(1):64-72
pubmed: 31260600
World J Urol. 2015 Dec;33(12):1945-50
pubmed: 25947885
Transl Androl Urol. 2020 Aug;9(4):1786-1793
pubmed: 32944541
BJU Int. 2009 Feb;103(3):307-11
pubmed: 18990163
Eur Urol. 2010 Apr;57(4):575-81
pubmed: 19959276
Eur Urol Focus. 2019 May;5(3):457-466
pubmed: 29366854
Eur Urol. 2014 Mar;65(3):650-8
pubmed: 24070577
Curr Urol Rep. 2016 May;17(5):36
pubmed: 26968416
Eur Urol. 2021 Jan;79(1):62-79
pubmed: 32593530
Eur Urol. 2011 Oct;60(4):703-10
pubmed: 21684068
Clin Genitourin Cancer. 2018 Jun;16(3):e669-e675
pubmed: 29239844
Eur Urol. 2003 Dec;44(6):656-60
pubmed: 14644116
Eur Urol. 2011 May;59(5):702-7
pubmed: 21296482
Eur Urol. 2010 Oct;58(4):574-80
pubmed: 20637540

Auteurs

Frederik König (F)

Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, 1090 Vienna, Austria.
Department of Urology, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany.

Nico C Grossmann (NC)

Department of Urology, University Hospital Zurich, 8091 Zurich, Switzerland.
Department of Urology, Luzerner Kantonsspital, 6004 Lucerne, Switzerland.

Francesco Soria (F)

Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, 10124 Turin, Italy.

David D'Andrea (D)

Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, 1090 Vienna, Austria.

Tristan Juvet (T)

Department of Urology, Lions Gate Hospital, North Vancouver, BC V7L 2L7, Canada.

Aaron Potretzke (A)

Department of Urology, Mayo Clinic, Rochester, MN 55905, USA.

Hooman Djaladat (H)

Department of Urology, USC/Norris Comprehensive Cancer Center, Los Angeles, CA 90033, USA.

Alireza Ghoreifi (A)

Department of Urology, USC/Norris Comprehensive Cancer Center, Los Angeles, CA 90033, USA.

Eiji Kikuchi (E)

Department of Urology, St. Marianna University School of Medicine, Kawasaki 216-8511, Japan.

Nozomi Hayakawa (N)

Department of Urology, St. Marianna University School of Medicine, Kawasaki 216-8511, Japan.

Andrea Mari (A)

Unit of Oncologic Minimally-Invasive Urology and Andrology, Department of Experimental and Clinical Medicine, Careggi Hospital, University of Florence, 50134 Florence, Italy.

Zine-Eddine Khene (ZE)

Department of Urology, University of Rennes, 35000 Rennes, France.

Kazutoshi Fujita (K)

Department of Urology, Faculty of Medicine, Kindai University, Osaka 577-8502, Japan.

Jay D Raman (JD)

Division of Urology, Department of Surgery, College of Medicine, The Pennsylvania State University, Hershey, PA 16801, USA.

Alberto Breda (A)

Urology Department, Fundació Puigvert, Autonomous University of Barcelona, 08193 Barcelona, Spain.

Matteo Fontana (M)

Urology Department, Fundació Puigvert, Autonomous University of Barcelona, 08193 Barcelona, Spain.

John P Sfakianos (JP)

Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.

John L Pfail (JL)

Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.

Ekaterina Laukhtina (E)

Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, 1090 Vienna, Austria.
Institute for Urology and Reproductive Health, Sechenov University, 119048 Moscow, Russia.

Pawel Rajwa (P)

Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, 1090 Vienna, Austria.
Department of Urology, Medical University of Silesia, 41-808 Zabrze, Poland.

Maximilian Pallauf (M)

Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, 1090 Vienna, Austria.
Department of Urology, Paracelsus Medical University Salzburg, University Hospital Salzburg, 5020 Salzburg, Austria.

Giovanni E Cacciamani (GE)

USC Institute of Urology, Keck Medicine of USC, University of Southern California, Los Angeles, CA 90007, USA.

Thomas van Doeveren (T)

Department of Urology, Erasmus MC Cancer Institute, University Medical Center, 3015 GD Rotterdam, The Netherlands.

Joost L Boormans (JL)

Department of Urology, Erasmus MC Cancer Institute, University Medical Center, 3015 GD Rotterdam, The Netherlands.

Alessandro Antonelli (A)

Department of Urology, Azienda Ospedaliera Universitaria Integrata of Verona, University of Verona, 37129 Verona, Italy.

Marcus Jamil (M)

Vattikuti Urology Institute, Henry Ford Hospital, Detroit, MI 48202, USA.

Firas Abdollah (F)

Vattikuti Urology Institute, Henry Ford Hospital, Detroit, MI 48202, USA.

Jeffrey Budzyn (J)

Vattikuti Urology Institute, Henry Ford Hospital, Detroit, MI 48202, USA.

Guillaume Ploussard (G)

Department of Urology, La Croix du Sud Hospital, 31130 Toulouse, France.

Axel Heidenreich (A)

Department of Urology, Uro-Oncology, Robot Assisted and Specialized Urologic Surgery, University Hospital Cologne, 50937 Cologne, Germany.

Siamak Daneshmand (S)

Department of Urology, USC/Norris Comprehensive Cancer Center, Los Angeles, CA 90033, USA.

Stephen A Boorjian (SA)

Department of Urology, Mayo Clinic, Rochester, MN 55905, USA.

Morgan Rouprêt (M)

Urology Department, GRC n°5, Predictive Onco-Uro, AP-HP, Pitié-Salpêtrière Hospital, Sorbonne University, 75006 Paris, France.

Michael Rink (M)

Department of Urology, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany.

Shahrokh F Shariat (SF)

Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, 1090 Vienna, Austria.
Institute for Urology and Reproductive Health, Sechenov University, 119048 Moscow, Russia.
Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman 19328, Jordan.
Karl Landsteiner Institute of Urology and Andrology, 1010 Vienna, Austria.
Department of Urology, Weill Cornell Medical College, New York, NY 10021, USA.
Department of Urology, University of Texas Southwestern, Dallas, TX 75390, USA.
Department of Urology, Second Faculty of Medicine, Charles University, 11638 Prague, Czech Republic.

Benjamin Pradere (B)

Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, 1090 Vienna, Austria.
Department of Urology, La Croix du Sud Hospital, 31130 Toulouse, France.

Classifications MeSH